Phio Pharma FY24 net loss $7.2M; PH-762 Phase 1b with complete responses; $12.1M raised

Phio Pharmaceuticals Corp.

2025-Q1 EPS reported -$0.41

Net loss for FY24 was $7.2M ($9.08/share), down from $10.8M ($46.76/share) in FY23.
Cash at Dec 31, 2024 was $5.4M; subsequent financings added net $6.8M, total $12.1M raised.
PH-762 Phase 1b: 3rd cohort fully enrolled; in cohort 2, 2 complete responses and 1 partial response out of 4 patients.
R&D expenses decreased 42% to $3.7M due to cost rationalization and termination of AgonOx agreement.
Total proceeds of $9.2M from registered direct offerings and $2.9M from warrant exercises.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.